ACE inhibitory casein peptide lowers blood pressure and reshapes gut microbiota in a randomized double blind placebo controlled trial

• Published in: Scientific reports Vol. 15; no. 1; pp. 13840 - 16
• Main Authors: Li, Kexin, Jiang, Peng, Li, Shuangqi, Sun, Jin, Qi, Ce
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22.04.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 692/699/75/243; 692/700/2814; 692/700/565/2072; Adult; Amino acids; Angiotensin; Angiotensin II; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Antihypertensive effect; Antihypertensives; Arginine; Blood pressure; Blood Pressure - drug effects; Casein; Casein hydrolysate; Caseins - chemistry; Caseins - pharmacology; Caseins - therapeutic use; Clinical trials; Double-Blind Method; Double-blind randomized placebo-controlled clinical study; Enzyme inhibitors; Enzymes; Female; Gastrointestinal Microbiome - drug effects; Gut microbiota; Humanities and Social Sciences; Humans; Hypertension; Hypertension - drug therapy; Inflammation; Intestinal microflora; Male; Microbiota; Middle Aged; multidisciplinary; Peptides; Peptidyl-dipeptidase A; Placebos; Science; Science (multidisciplinary); Valine; Hypertension; Microbiota; Casein hydrolysate; Double-blind randomized placebo-controlled clinical study; Antihypertensive effect

Casein-derived peptides have been shown to reduce blood pressure in animal studies, but evidence from human trials remains limited. This study aimed to investigate the antihypertensive effect and possible mechanisms of a hydrolyzed casein peptide tablet containing GPFPIIV and FFVAPFPEVFGK (HCP-C7C12...